Page last updated: 2024-08-21

diphenylamine and Carcinoma, Non-Small Cell Lung

diphenylamine has been researched along with Carcinoma, Non-Small Cell Lung in 12 studies

Research

Studies (12)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (16.67)	29.6817
2010's	9 (75.00)	24.3611
2020's	1 (8.33)	2.80

Authors

Authors	Studies
Beijnen, JH; Bernards, R; de Vos, FYFL; Devriese, LA; Eskens, FALM; Huijberts, SCFA; Huitema, ADR; Lolkema, MPJK; Marchetti, S; Monkhorst, K; Opdam, FL; Rosing, H; Schellens, JHM; Steeghs, N; Thijssen, B; van Brummelen, EMJ; van Geel, RMJM	1
Archibald, HL; Azzoli, CG; Benes, CH; Bilton, SJ; Brown, SP; Caenepeel, S; Cahill, DP; Coxon, A; Farago, AF; Ferris, LA; Fraser, C; Gainor, JF; Gomez-Caraballo, M; Hata, AN; Hughes, PE; Keyes, C; Lanuti, M; Li, C; Nangia, V; Phan, N; Piotrowska, Z; Raskin, KA; Rigas, D; Sarosiek, KA; Sequist, LV; Shin, JH; Siddiqui, FM; Timonina, D; Vajda, K; Wright, CD	1
Brekken, RA; Buettner, R; Chatterjee, S; Christofori, G; Frasca, D; Heukamp, LC; Koker, M; König, K; Meder, L; Neumaier, B; Peifer, M; Rauh, D; Schöttle, J; Siobal, M; Thomas, RK; Ullrich, RT; Wieczorek, C; Wolf, J	1
Chinn, DC; Gandara, DR; Holland, WS; Lara, PN; Mack, PC	1
Du, J; Liu, Q; Ni, Y; Pang, Z; Wang, L; Zhang, J	1
Fukazawa, T; Ishida, N; Kato, K; Maeda, Y; Matsumoto, K; Naomoto, Y; Shimo, T; Takigawa, N; Whitsett, JA; Yamatsuji, T	1
Chua, KN; Goh, BC; Huynh, H; Kong, LR; Ng, HC; Ong, WR; Sim, WJ; Thiery, JP	1
Banno, E; Chiba, M; De Velasco, MA; Fujita, Y; Hayashi, H; Mitsudomi, T; Mizuuchi, H; Nakamura, Y; Nishio, K; Sakai, K; Terashima, M; Togashi, Y; Tomida, S	1
Bazhenova, L; Cohen, RB; Eisenberg, PD; Gadgeel, SM; Haura, EB; Larson, TG; Miller, VA; Ricart, AD; Selaru, P; Stella, PJ; Wilner, KD	1
Juan, J; McMahon, M; Sweet-Cordero, A; Trejo, CL; Vicent, S	1
Adjei, AA	1
Horwitz, SB; Keller, SM; Legrier, ME; Lopez-Barcons, L; McDaid, HM; Pérez-Soler, R; Yan, HG; Yang, CP	1

Reviews

1 review(s) available for diphenylamine and Carcinoma, Non-Small Cell Lung

Article	Year
The role of mitogen-activated ERK-kinase inhibitors in lung cancer therapy. Clinical lung cancer, 2005, Volume: 7, Issue:3 Topics: Benzamides; Carcinoma, Non-Small-Cell Lung; Diphenylamine; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Genes, ras; Humans; Lung Neoplasms; MAP Kinase Signaling System; Mutation; raf Kinases; ras Proteins; Signal Transduction	2005

Trials

2 trial(s) available for diphenylamine and Carcinoma, Non-Small Cell Lung

Article	Year
Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer. British journal of cancer, 2020, Volume: 122, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Diphenylamine; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Mutation; Neoplasms; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Quinazolinones	2020
A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Apr-15, Volume: 16, Issue:8 Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Benzamides; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Diphenylamine; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Survival Rate; Tissue Distribution; Treatment Outcome	2010

Article

Year

Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer.

British journal of cancer, 2020, Volume: 122, Issue:8

Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Diphenylamine; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Mutation; Neoplasms; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Quinazolinones

2020

A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Apr-15, Volume: 16, Issue:8

Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Benzamides; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Diphenylamine; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Survival Rate; Tissue Distribution; Treatment Outcome

2010

Other Studies

9 other study(ies) available for diphenylamine and Carcinoma, Non-Small Cell Lung

Article	Year
Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in Cancer discovery, 2018, Volume: 8, Issue:12 Topics: A549 Cells; Aniline Compounds; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Diphenylamine; Humans; Lung Neoplasms; Mice, Knockout; Mice, Nude; Mice, SCID; Mitogen-Activated Protein Kinase Kinases; Myeloid Cell Leukemia Sequence 1 Protein; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Sulfonamides; Tumor Burden; Xenograft Model Antitumor Assays	2018
Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer. The Journal of clinical investigation, 2013, Volume: 123, Issue:4 Topics: Animals; Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Transformation, Neoplastic; Diphenylamine; Feedback, Physiological; Humans; Lung Neoplasms; MAP Kinase Signaling System; Mice; Mice, Nude; Neovascularization, Pathologic; Piperidines; Quinazolines; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2	2013
Effects of AKT inhibition on HGF-mediated erlotinib resistance in non-small cell lung cancer cell lines. Journal of cancer research and clinical oncology, 2015, Volume: 141, Issue:4 Topics: Apoptosis; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Diphenylamine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Hepatocyte Growth Factor; Heterocyclic Compounds, 3-Ring; Humans; Immunoblotting; Lung Neoplasms; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; ras Proteins	2015
PKD1 is downregulated in non-small cell lung cancer and mediates the feedback inhibition of mTORC1-S6K1 axis in response to phorbol ester. The international journal of biochemistry & cell biology, 2015, Volume: 60 Topics: Aminopyridines; Benzamides; Blotting, Western; Butadienes; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chromones; Diphenylamine; Enzyme Activation; Humans; Mechanistic Target of Rapamycin Complex 1; Morpholines; Multiprotein Complexes; Nitriles; Phorbol Esters; Real-Time Polymerase Chain Reaction; Ribosomal Protein S6 Kinases, 70-kDa; TOR Serine-Threonine Kinases; TRPP Cation Channels	2015
A novel PI3K inhibitor iMDK suppresses non-small cell lung Cancer cooperatively with A MEK inhibitor. Experimental cell research, 2015, Jul-15, Volume: 335, Issue:2 Topics: Animals; Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Coumarins; Diphenylamine; Drug Synergism; Female; Human Umbilical Vein Endothelial Cells; Humans; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Mitogen-Activated Protein Kinase Kinases; Neovascularization, Pathologic; Phosphoinositide-3 Kinase Inhibitors; Thiazoles; Xenograft Model Antitumor Assays	2015
Combinatorial treatment using targeted MEK and SRC inhibitors synergistically abrogates tumor cell growth and induces mesenchymal-epithelial transition in non-small-cell lung carcinoma. Oncotarget, 2015, Oct-06, Volume: 6, Issue:30 Topics: Animals; Benzamides; Benzodioxoles; Cadherins; Carcinoma, Non-Small-Cell Lung; Cell Adhesion; Cell Cycle; Cell Movement; Cell Proliferation; Diphenylamine; Dose-Response Relationship, Drug; Drug Synergism; Epithelial-Mesenchymal Transition; Female; Humans; Immunoblotting; Lung Neoplasms; MAP Kinase Kinase 1; Mice, Inbred BALB C; Mice, Nude; Microscopy, Confocal; Protein Kinase Inhibitors; Quinazolines; src-Family Kinases; Tumor Burden; Xenograft Model Antitumor Assays	2015
MEK inhibitors against MET-amplified non-small cell lung cancer. International journal of oncology, 2016, Volume: 49, Issue:6 Topics: A549 Cells; Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Crizotinib; Diphenylamine; ErbB Receptors; Humans; Lung Neoplasms; MAP Kinase Kinase 1; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Pyridones; Pyrimidinones	2016
MEK1/2 inhibition elicits regression of autochthonous lung tumors induced by KRASG12D or BRAFV600E. Cancer research, 2012, Jun-15, Volume: 72, Issue:12 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Diphenylamine; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; Lung Neoplasms; MAP Kinase Kinase 1; MAP Kinase Kinase 2; MAP Kinase Signaling System; Mice; Mice, Transgenic; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Respiratory Mucosa; Tumor Cells, Cultured	2012
Targeting protein translation in human non small cell lung cancer via combined MEK and mammalian target of rapamycin suppression. Cancer research, 2007, Dec-01, Volume: 67, Issue:23 Topics: Animals; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Death; Cell Proliferation; Diphenylamine; Drug Synergism; Drug Therapy, Combination; Feedback, Physiological; Humans; Immunoblotting; Immunosuppressive Agents; Lung Neoplasms; Mice; Mice, Nude; Mitogen-Activated Protein Kinase Kinases; Peptide Chain Initiation, Translational; Protein Kinases; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases	2007